Statement of the Polish Gynecological Society Expert Group on the use of iron preparations (Tardyferon, Tardyferon-Fol) in obstetrics and gynaecology

Abstract

According to the literature data, approximately 700 million people worldwide have overt or latent iron deficiency. This is related to nutrition. The highest risk groups, apart from children, are pregnant women (50–60%) and young women of childbearing age (20–40%). Anaemia is a hazard for pregnant and parturient women, as well as for the foetus and newborn. In pregnant women, pharmacological treatment should be initiated if parameters such as haemoglobin, iron and ferritin levels indicate existing iron deficiency or overt anaemia. Treatment should be administered in each period of pregnancy. Commonly recommended anaemia management includes two actions:  a diet rich in iron and therapy with preparations containing iron with folic acid. Oral, well-tolerated and sustainedrelease iron products are preferred. Formulations containing divalent iron, slowly-absorbed, causing no  astrointestinal intolerance, which are available on the Polish market, include Tardyferon and  Tardyferon-Fol. These products fully meet WHO requirements for recommended daily intake of elemental iron in patients with anaemia or iron deficiency. In the opinion of the Polish Gynaecological Society Panel of Experts, iron preparations Tardyferon and Tardyferon-Fol are effective therapeutic options for the prevention and treatment of iron deficiency anaemia.